# Defining the Ablative Dose for Y-90 TARE

> **NCT07586046** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwestern University** · enrollment: 30 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **OTHER:** Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres

## Key facts

- **NCT ID:** NCT07586046
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-02
- **Final completion:** 2029-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07586046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07586046, "Defining the Ablative Dose for Y-90 TARE". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT07586046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*